A Brisbane-based company that invented a smartphone app it says can diagnose COVID-19 and other respiratory illnesses by listening to someone cough has been purchased by Pfizer for nearly $180 million.
ResApp Health Limited uses diagnostic technology developed by Associate Professor Udantha Abeyratne and his research team at the University of Queensland (UQ) to record and analyse a patient's coughs on a smartphone.